Neurent Medical

Neurent Medical

Galway, Ireland· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $70M

Overview

Neurent Medical is a commercial-stage medical device company focused on innovating treatments for chronic rhinitis. Its core technology, the NEUROMARK System, is a clinically proven, minimally invasive procedure that uses low-power energy to disrupt the posterior nasal nerves, aiming for lasting symptom relief with minimal downtime. The company is targeting the large and underserved patient population suffering from chronic rhinitis, positioning itself as a provider of a targeted, in-office solution for ENT specialists.

Chronic RhinitisOtorhinolaryngology (ENT)

Technology Platform

Minimally invasive neuromodulation platform using low-power, temperature-controlled radiofrequency energy and real-time apposition confirmation to target overactive nerves in chronic inflammatory conditions.

Funding History

2
Total raised:$70M
Series B$45M
Series A$25M

Opportunities

The primary opportunity lies in capturing a significant share of the large, underserved chronic rhinitis patient population dissatisfied with pharmacological management.
As a minimally invasive, in-office procedure with durable results, NEUROMARK is well-positioned to fill the gap between drugs and surgery.

Risk Factors

Key risks include the challenge of commercial execution and building market adoption in a competitive landscape, uncertainty and delays in securing favorable insurance reimbursement, and the need to demonstrate long-term durability and safety of the treatment to maintain physician and patient confidence.

Competitive Landscape

NEUROMARK competes in the minimally invasive rhinitis treatment market against other office-based devices using technologies like cryotherapy (e.g., ClariFix) and other radiofrequency systems. It also competes indirectly with continued pharmacological management and more invasive surgical procedures. Differentiation is based on its targeted posterior nasal nerve approach, apposition confirmation technology, and clinical data.